Recent Updates in Relapsed or Refractory Multiple Myeloma

June 4th 2021

Key opinion leaders discuss recent updates in treating relapsed or refractory multiple myeloma.

Update on EGFR Antibodies in mCRC

May 25th 2021

Recommendations for appropriately managing metastatic colorectal cancer with anti-EGFR therapy based on recent changes to cetuximab dosing.

Triple-Class Refractory Multiple Myeloma

May 4th 2021

Recommendations for sequencing therapies for triple-class refractory myeloma with options such as selinexor, belantamab mafodotin, or melflufen.

New Targets to Improve Patient Outcomes in MZL and FL

April 20th 2021

Experts in hematology and medical oncology, Anthony Mato, MD, MSCE, and Lori A. Leslie, MD, discuss the current therapeutic options available for marginal zone lymphoma and follicular lymphoma and provide key insights into how the recent accelerated approval of umbralisib has impacted the treatment landscape.

Exploring Immunotherapy Combinations in Endometrial Cancer

April 14th 2021

Experts in gynecologic oncology review key advances in treating advanced endometrial cancer and the promise of combination immunotherapy-based regimens.

Graft Versus Host Disease

April 13th 2021

Corey S. Cutler, MD, MPH, FRCPC; Yi-Bin Chen, MD; and Haris Ali, MD, review currently available treatment options for acute and chronic GVHD and discuss the management of steroid-refractory disease.

Combinations are the Future in FLT3-Mutated AML

March 31st 2021

MET Exon 14 Skipping Mutations in Non–Small Cell Lung Cancer

March 29th 2021

Small-Cell Lung Cancer

March 25th 2021

Individualizing Treatment Approaches in MPN

February 26th 2021